Madison Asset Management LLC Takes $543,000 Position in Abbott Laboratories $ABT

Madison Asset Management LLC purchased a new position in Abbott Laboratories (NYSE:ABT) during the second quarter, Holdings Channel reports. The fund purchased 5,989 shares of the healthcare product maker’s stock, valued at approximately $543,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Nia Impact Advisors LLC raised its position in Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the period. Riggs Asset Managment Co. Inc. grew its position in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 88 shares during the period. Eley Financial Management Inc increased its stake in shares of Abbott Laboratories by 0.9% during the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock worth $1,355,000 after purchasing an additional 92 shares during the last quarter. Copley Financial Group Inc. increased its stake in shares of Abbott Laboratories by 2.1% during the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after purchasing an additional 93 shares during the last quarter. Finally, Kelleher Financial Advisors raised its holdings in shares of Abbott Laboratories by 2.9% in the 3rd quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 93 shares during the period. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analyst Ratings Changes

Several brokerages have weighed in on ABT. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. TD Cowen upped their price target on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Wells Fargo & Company increased their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Trading Up 0.9%

Shares of Abbott Laboratories stock opened at $112.63 on Friday. The company’s 50-day moving average price is $102.61 and its 200-day moving average price is $100.22. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a market cap of $194.89 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.